NASDAQ : ACRV
Acrivon Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.66 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 71.14M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 20.97M | 24.12M | 25.21M | 21.08M | 8.71M | 2.47M |
| Research & Development | 57.40M | 59.99M | 63.99M | 46.02M | 23.95M | 13.72M |
| Operating Expenses | 78.37M | 84.11M | 89.20M | 67.10M | 32.66M | 16.18M |
| Operating Income | -78.37M | -84.11M | -89.20M | -67.10M | -32.66M | -16.18M |
| Interest & Investment Income | 4.60M | 6.48M | 9.20M | 7.04M | ||
| Currency Exchange Gain (Loss) | 200.00K | 200.00K | -100.00K | |||
| Other Non Operating Income (Expenses) | -1.09M | -907.00K | -4.24M | -3.65M | 792.00K | -59.00K |
| EBT Excluding Unusual Items | -74.66M | -78.34M | -84.33M | -63.71M | -31.86M | -16.24M |
| Gain (Loss) on Sale of Investments | 437.00K | 437.00K | 3.78M | 3.32M | 698.00K | |
| Pretax Income | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Net Income | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Net Income to Common | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Shares Outstanding (Basic) | 39.45M | 38.51M | 33.79M | 22.08M | 4.12M | 1.74M |
| Shares Outstanding (Diluted) | 39.45M | 38.51M | 33.79M | 22.08M | 4.12M | 1.74M |
| EPS (Basic) | -1.88 | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| EPS (Diluted) | -1.88 | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| Free Cash Flow | -64.14M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Free Cash Flow Per Share | -1.63 | -1.70 | -2.02 | -1.99 | -7.83 | -8.16 |
| EBITDA | -76.88M | -82.76M | -88.19M | -66.57M | -32.29M | -16.15M |
| D&A For EBITDA | 1.50M | 1.36M | 1.01M | 536.00K | 364.00K | 37.00K |
| EBIT | -78.37M | -84.11M | -89.20M | -67.10M | -32.66M | -16.18M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 41.42M | 41.50M | 39.82M | 36.02M | 29.52M | 99.60M |
| Short-Term Investments | 48.54M | 77.08M | 139.66M | 91.44M | 98.23M | |
| Cash & Short-Term Investments | 89.96M | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Prepaid Expenses | 1.53M | 1.86M | 2.15M | 2.23M | 4.34M | 805.00K |
| Total Current Assets | 91.49M | 120.44M | 181.63M | 129.69M | 132.09M | 100.41M |
| Property, Plant & Equipment | 6.22M | 7.42M | 8.03M | 7.91M | 6.86M | 5.79M |
| Long-Term Investments | 5.09M | 41.88M | ||||
| Long-Term Deferred Charges | 500.00K | |||||
| Other Long-Term Assets | 1.37M | 1.36M | 1.84M | 665.00K | 388.00K | 388.00K |
| Total Assets | 99.09M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Accounts Payable | 861.00K | 2.28M | 758.00K | 5.05M | 904.00K | 964.00K |
| Accrued Expenses | 9.45M | 12.07M | 15.40M | 7.38M | 4.14M | 1.22M |
| Current Portion of Leases | 1.14M | 1.17M | 1.06M | 877.00K | 726.00K | 664.00K |
| Current Unearned Revenue | 69.00K | 66.00K | ||||
| Other Current Liabilities | 143.00K | 673.00K | ||||
| Total Current Liabilities | 11.45M | 15.66M | 17.21M | 13.30M | 6.52M | 2.91M |
| Long-Term Leases | 980.00K | 1.54M | 2.59M | 3.77M | 4.24M | 4.96M |
| Total Liabilities | 12.43M | 17.20M | 19.80M | 17.07M | 10.75M | 7.88M |
| Common Stock | 42.00K | 31.00K | 31.00K | 23.00K | 22.00K | 2.00K |
| Additional Paid-In Capital | 398.54M | 387.25M | 373.28M | 237.68M | 226.58M | 1.05M |
| Retained Earnings | -311.89M | -274.88M | -196.98M | -116.42M | -56.03M | -24.86M |
| Comprehensive Income & Other | -33.00K | 111.00K | 447.00K | -83.00K | -95.00K | |
| Total Common Equity | 86.67M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
| Shareholders' Equity | 86.67M | 112.52M | 176.79M | 121.19M | 170.47M | 98.71M |
| Total Liabilities & Equity | 99.09M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Total Debt | 2.12M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Net Cash (Debt) | 87.84M | 115.87M | 175.84M | 122.81M | 122.79M | 93.97M |
| Net Cash Per Share | 2.23 | 3.01 | 5.20 | 5.56 | 29.79 | 53.90 |
| Filing Date Shares Outstanding | 42.85M | 38.74M | 31.35M | 22.64M | 21.92M | 1.77M |
| Total Common Shares Outstanding | 42.85M | 31.65M | 31.23M | 22.52M | 21.92M | 1.77M |
| Working Capital | 80.05M | 104.78M | 164.41M | 116.39M | 125.58M | 97.49M |
| Book Value Per Share | 2.02 | 3.56 | 5.66 | 5.38 | 7.78 | -13.45 |
| Tangible Book Value | 86.67M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
| Tangible Book Value Per Share | 2.02 | 3.56 | 5.66 | 5.38 | 7.78 | -13.45 |
| Machinery | 8.35M | 7.29M | 6.38M | 3.13M | 2.51M | 346.00K |
| Construction In Progress | 916.00K | 58.00K | 1.31M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -74.22M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Depreciation & Amortization | 1.50M | 1.36M | 1.01M | 536.00K | 364.00K | 37.00K |
| Loss (Gain) From Sale of Investments | 318.00K | -437.00K | -3.78M | -3.32M | -698.00K | |
| Stock-Based Compensation | 11.40M | 14.72M | 14.29M | 11.62M | 2.19M | 497.00K |
| Other Operating Activities | 1.07M | 1.03M | 932.00K | 778.00K | 731.00K | 1.40M |
| Change in Accounts Payable | -144.00K | 1.54M | -3.59M | 3.61M | -245.00K | 798.00K |
| Change in Other Net Operating Assets | -2.84M | -3.96M | 6.02M | 4.53M | -1.29M | -470.00K |
| Operating Cash Flow | -62.92M | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Capital Expenditures | -1.22M | -1.67M | -2.77M | -1.29M | -2.17M | -238.00K |
| Investment in Securities | 56.73M | 67.77M | -49.00M | 52.01M | -139.51M | |
| Investing Cash Flow | 55.51M | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Issuance of Common Stock | 7.31M | 1.00K | 70.09M | 775.00K | 104.48M | 1.00K |
| Repurchase of Common Stock | -376.00K | -750.00K | -2.52M | -1.30M | ||
| Other Financing Activities | -4.00K | 53.46M | -1.03M | -2.77M | ||
| Financing Cash Flow | 6.93M | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
| Net Cash Flow | -484.00K | 1.69M | 3.59M | 6.52M | -70.08M | 98.00M |
| Free Cash Flow | -64.14M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Free Cash Flow Per Share | -1.63 | -1.70 | -2.02 | -1.99 | -7.83 | -8.16 |
| Levered Free Cash Flow | -39.82M | -39.54M | -39.41M | -22.33M | -20.03M | -8.79M |
| Unlevered Free Cash Flow | -39.82M | -39.54M | -39.41M | -22.33M | -20.03M | -8.79M |
| Change in Working Capital | -2.98M | -2.43M | 2.44M | 8.14M | -1.53M | 328.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 71.14M | 76.05M | 187.44M | 109.20M | 240.59M | |
| Enterprise Value | -16.71M | -50.22M | 4.00M | -28.47M | 291.43M | |
| Last Close Price | 1.66 | 2.41 | 6.02 | 4.92 | 11.52 | |
| PB Ratio | 0.82 | 0.68 | 1.06 | 0.90 | 1.41 | |
| P/TBV Ratio | 0.82 | 0.68 | 1.06 | 0.90 | 1.41 | |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | 0.06 |
| Net Debt / Equity Ratio | -1.01 | -1.03 | -0.99 | -1.01 | -0.72 | -0.95 |
| Net Debt / EBITDA Ratio | 1.14 | 1.40 | 1.99 | 1.84 | 3.80 | 5.82 |
| Net Debt / FCF Ratio | 1.37 | 1.77 | 2.57 | 2.80 | 3.80 | 6.61 |
| Quick Ratio | 7.86 | 7.57 | 10.43 | 9.58 | 19.61 | 34.18 |
| Current Ratio | 7.99 | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 |
| Return on Equity (ROE) | -64.63% | -53.86% | -54.07% | -41.41% | -23.16% | -32.40% |
| Return on Assets (ROA) | -38.02% | -32.22% | -33.30% | -26.25% | -14.18% | -18.60% |
| Return on Capital Employed (ROCE) | -89.40% | -73.70% | -49.70% | -53.70% | -18.70% | -15.60% |
| Earnings Yield | -113.34% | -102.44% | -42.98% | -55.30% | -12.95% | |
| FCF Yield | -90.16% | -85.91% | -36.51% | -40.23% | -13.42% | |
| Buyback Yield / Dilution | -2.97% | -13.96% | -53.05% | -435.63% | -136.43% | -21.70% |